Grace Therapeutics

Historical price data

Grace Therapeutics is a public, clinical-stage biotech company focused on discovering and developing novel therapeutics for rare neurological and neurodevelopmental disorders. Its core strategy is built on a proprietary platform targeting specific neuronal ion channels to address hyperexcitability disorders, with lead programs in rare focal epilepsies and treatment-resistant seizures. The company is actively enrolling patients in Phase 2 and Phase 1/2 trials, positioning itself in a high-need, growing segment of the neurology market. Founded in 2019, Grace seeks to build a sustainable R&D engine to advance its pipeline and address significant unmet medical needs.

A proprietary platform focused on designing selective small molecule modulators of specific neuronal ion channels and receptors to treat CNS hyperexcitability disorders, integrating computational modeling, structural biology, and high-throughput screening.

Faces competition from both large pharma and specialized biotechs across its target indications. In rare epilepsies, competition is fragmented by genetic target; in treatment-resistant epilepsy, it must differentiate against a crowded field of approved and pipeline anti-seizure medications.